Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Contraceptive advisory: Norplant contraceptive recipients can discontinue use of any "backup, non-hormonal method of birth control," developer Wyeth and FDA agree. Wyeth had advised doctors in October 2000 to discontinue implanting the system from lots going into distribution beginning in October 1999, based on concern about lower-than-expected release of the hormone levonorgestrel from the implants. Though the concerns have been resolved, Wyeth will stop selling the six-capsule Norplant system due to limitations in the component supply and therefore recommends women implanted with the devices seek alternative contraceptive methods when their implants expire...
You may also be interested in...
Australia TGA To Hold May, June Seminars On New Device Regulation Laws
Australia's Therapeutic Goods Administration will draft guidance documents explaining legislative requirements under the recently enacted Therapeutic Goods Amendment (Medical Devices) Bill and the Therapeutic Goods (Charges) Amendment Bill
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.